Video
Author(s):
Nelson J. Chao, MD, MBA, explains the frontline treatment options for chronic GVHD, and when to consider restarting an immunosuppressive regimen.
DK210 (EGFR) Induces Immune Response Without Increased CRS or Regulatory T Cells in Solid Tumors
Siglec-15 Represents Potential Therapeutic Target in NSCLC, Other Solid Tumors
Radiomic Biomarkers Predict Response in Lung and Liver Uveal Melanoma Metastases
BT7480 Shows Preliminary Activity in Nectin-4+, CD137+ Tumors
2 Commerce Drive
Cranbury, NJ 08512